AAM
TXMD icon

American Asset Management’s TherapeuticsMD TXMD Stock Holding History

American Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-284
Closed -$82K – 92
2016
Q4 		$82K Buy
+284
New +$88K 0.09% 78

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

American Asset Management's TXMD Position: Q1 2017 in Review

American Asset Management sold out of TherapeuticsMD (TXMD) in Q1 2017, closing a stake of 284 shares — an estimated $82K sold.

American Asset Management first reported a position in TXMD in Q4 2016 and held it in 1 quarter. The position peaked at $82K in Q4 2016. 138 funds tracked by Wall St. Rank hold TXMD as of Q1 2017.

  • American Asset Management reported no remaining TherapeuticsMD position as of Q1 2017 after selling out during the quarter.
  • American Asset Management sold 284 TherapeuticsMD shares in Q1 2017, an estimated $82K.
  • American Asset Management first reported a position in TherapeuticsMD in Q4 2016 and held it in 1 quarter.
  • American Asset Management's TherapeuticsMD position peaked at $82K in Q4 2016.
  • 138 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2017.

Based on American Asset Management's 13F filing for Q1 2017, filed 5 May 2017.